Daniel S. Lorrain, Chief Scientific Officer at Contineum Therapeutics, Inc. (CTNM), sold 8,340 shares at $14.82 ($125K) on 2026-02-03, disclosed to the SEC on 2026-02-05.
Open-market sale of $125k CTNM by Chief Scientific Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $14.82 | 3,000 | $44K | 35.7% |
| 2 | $14.82 | 3,000 | $44K | 35.7% |
| 3 | $15.25 | 1,170 | $18K | 14.3% |
| 4 | $15.25 | 1,170 | $18K | 14.3% |
| Total | $14.94 avg | 8,340 | $125K | 100% |
| Filing → |
| CTNM | SELL | 2026-06-01 | $55K | — | Filing → |
| CTNM | SELL | 2026-05-01 | $55K | — | Filing → |
| CTNM | SELL | 2026-04-06 | $56K | — | Filing → |